Dr. Lal PathLabs (LALPATHLAB) Q1 FY27 Profit Jumps 27% as Margins Widen
The diagnostics leader posted its fastest quarterly revenue growth in four years, with profit rising faster on better test mix and government pricing tailwinds.
Dr. Lal PathLabs reported a 19.1% rise in Q1 FY27 revenue to ₹798 crore, its strongest quarterly growth in four years. Net profit grew even faster at 27.2% to ₹170.5 crore, as margins expanded on a favorable test mix and government pricing benefits.
Dr. Lal PathLabs entered FY27 with its strongest operating momentum in years. The quarter saw revenue growth accelerate to a four-year high, but the real story was profit rising even faster as the company's margin engine finally kicked into gear.
Revenue for the quarter ended June 2026 stood at ₹797.7 crore, a 19.1% jump from a year ago and 13.5% higher than the March quarter. Profit after tax reached ₹170.5 crore, growing 27.2% year-on-year. The net profit margin expanded by 140 basis points to 21.4%, showing the business is gaining operating leverage.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 797.7YoY +19% | 702.7 | 669.8 |
| Profit (₹ Cr) | 170.5YoY +27% | 132.2 | 134.0 |
| Net Profit Margin (%) | 21.4YoY +7% | 18.8 | 20.0 |
The Three-Pronged Growth Engine
Management, in its earnings call covered by Investing.com and Quartr, attributed the growth to a powerful combination. Patient volumes grew 8.2% and sample volumes rose 10.7%, indicating people are taking more tests. Revenue per patient jumped 10% to ₹968.
This realization gain came from a better test and geography mix, and a crucial 2-3% boost from recent CGHS and ECHS government scheme price increases. CEO Shankha Banerjee told CNBC-TV18 this pricing tailwind should continue for another two to three quarters.
Why Margins Finally Expanded
Profit growth outpaced revenue thanks to significant operating leverage. According to reports from Bajaj Broking and Investing.com, EBITDA margin expanded 230 basis points to 31%. Costs like material consumption and fees to collection centres rose largely in line with volume growth, not faster.
This marks a recovery from a weak Q3 FY26, where profit was depressed by a one-time ₹30 crore Labour Code cost, as noted by Quartr. The business has returned to a more normalized, profitable growth trajectory.
A Guarded Upgrade for the Year Ahead
While the start was strong, management is holding its formal guidance steady for now. The company maintained its full-year EBITDA margin target of 27-28%, as reported by Quartr, indicating it may reinvest some of the Q1 margin benefit.
However, the revenue outlook got a nudge. Leadership now says FY27 growth is more likely to be in the mid-teens than the early-teens range previously guided. A formal upgrade will be considered after the second quarter.
Key Points
- Revenue grew 19.1% YoY to ₹797.7 crore, the fastest quarterly pace in four years, driven by 8.2% patient volume growth and a 10% rise in revenue per patient.
- Net profit jumped 27.2% YoY to ₹170.5 crore, with the margin expanding 140 basis points to 21.4% on operating leverage and a favorable test mix.
- A 2-3% revenue boost from CGHS/ECHS government pricing increases provided a tailwind expected to last another two to three quarters.
- Management maintained its FY27 EBITDA margin guidance of 27-28% but indicated full-year revenue growth is now biased toward the mid-teens.
- The company plans to add 12-15 new labs and 3-4 radiology centers this year, with a capex budget of ₹140-150 crore.
Hexa Perspective
The quarter demonstrates Dr. Lal PathLabs' ability to drive profitable, volume-led growth in a stable pricing environment. The margin expansion is particularly encouraging, showing the scalability of its network after years of investment.
The near-term outlook is supported by the transitory CGHS pricing benefit, but the core story rests on sustaining high single-digit volume growth and a premium test mix. Investors will watch the second quarter closely to see if this strong start is the new baseline or a seasonal peak.
With a debt-free balance sheet holding over ₹1,693 crore in cash, the company has ample firepower for expansion and acquisitions. The key will be deploying that capital into projects that extend this new phase of profitable growth beyond the current tailwinds.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.